Implementation of Smoking Cessation in Current Smokers Within NCI NCORP Community Sites
Evaluate a multi-faceted training program to improve short-term smoking cessation rates (< 14 days post-visit) and short (3 months) and sustained abstinence (6 months) among 1,114-1,300 enrolled smokers who present for low-dose computed tomography (LDCT) lung cancer screening in 26 community-based practices.
Inclusion Criteria
- PATIENT: Age 55-77, reflecting the age criteria for the United States Preventive Services Task Force (USPSTF) guideline-approved referral for lung screening
- PATIENT: Patient participants must also be a current smoker, defined as anyone who responds “every day” or “some days” to the question: “Do you smoke cigarettes every day, some days, or not at all?” (Behavioral Risk Factor Surveillance System [BRFSS])
- PATIENT: Patients with a history of lung and/or other cancer(s) (who do not have current signs or symptoms of lung cancer) will be eligible
- KEY INFORMANT: Member of the lung cancer screening team who is (or would be) responsible for implementation and/or supporting smoking cessation support for patients receiving lung cancer screening; this will include the program champion (intervention clinic only) and is likely to include: imaging facility program directors, health care providers (e.g., physicians, radiological technicians), and other staff (e.g., receptionist); coordinators of centralized services for tobacco cessation at the component/subcomponent would also be eligible
- KEY INFORMANT: Agrees to participate in a confidential 1-on-1 semi-structured interview with the research team
- KEY INFORMANT: Agrees to have the interview taped, transcribed and qualitatively analyzed
Exclusion Criteria
- PATIENT: Current use (previous 30 days) of a tobacco dependence treatment including bupropion, varenicline, and nicotine replacement because the person is trying to quit; use of bupropion for depression does not exclude the patient from participating; the occasional use of tobacco dependence treatment (e.g., nicotine replacement therapy [NRT]) to avoid using tobacco in public spaces is not considered to be an exclusion criteria
- PATIENT: Individuals who use e-cigarettes and who are not smoking cigarettes; dual users (those who use both e-cigarettes and cigarettes) will be included in the trial
- PATIENT: The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia)
- PATIENT: Individual has already completed the intended LDCT lung cancer screening for this study
- PATIENT: Non-English speaking
- KEY INFORMANT: Unwilling to participate
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03291587.
PRIMARY OBJECTIVES:
I. Evaluate a multi-faceted training program to improve immediate (=< 14 days after the screening visit), short-term (3 months after the screening visit) and sustained abstinence (6 months after the screening visit) among 1,114-1,300 enrolled smokers who present for LDCT lung cancer screening in 26 community-based practices.
II. Characterize the adoption and adaptation of evidence-based tobacco cessation strategies in 26 diverse, community-based LDCT lung cancer screening imaging facilities within National Cancer Institute Community Oncology Research Program (NCORP) components/subcomponents.
III. Develop and evaluate an implementation toolkit for integrating evidence-based tobacco cessation strategies in community-based LDCT lung cancer screening imaging facilities.
OUTLINE:
We utilize an effectiveness-implementation hybrid design, employing a cluster, randomized control trial of community-based NCORP sites to study the effectiveness of a multi-faceted intervention to improve smoking cessation among lung cancer screening patients, as well as dissemination and implementation (D&I) science to optimize and accelerate translation of findings into clinical practice. We will: (1) Evaluate a multi-faceted training program to improve short-term smoking cessation rates (1-week post-visit) and sustained abstinence (6 months) among 1,114 enrolled smokers (557 in each trial arm) who present for LDCT lung cancer screening in community-based lung cancer screening practices; (2) Characterize the adoption and adaptation of the evidence-based tobacco cessation strategies in 26 community-based LDCT lung cancer screening programs; and (3) Develop and evaluate an implementation toolkit for integrating evidence-based tobacco cessation strategies in community-based LDCT lung cancer screening programs. Qualitative data will be collected from key informants at participating screening programs during and after intervention implementation. Quantitative survey data (baseline, <14 days, 3 months, and 6 months) and saliva specimens (6 months only) will be collected from smoking patients receiving screening within these programs.
Trial PhaseNo phase specified
Trial Typeprevention
Lead OrganizationWake Forest NCORP Research Base
Principal InvestigatorKristie Foley
- Primary ID20817CD
- Secondary IDsNCI-2017-01669, WF-20817CD
- ClinicalTrials.gov IDNCT03291587